AdvanceAD-Tx test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis

A prospective, multi-center observational study developed and validated the AdvanceAD-Tx non-invasive gene expression profile test to guide systemic therapy for atopic dermatitis.  The study demonstrated that patients identified with a JAK Inhibitor Responder Profile were significantly more likely to achieve higher rates of skin clearance (EASI-90, vIGA-AD 0, BSA 0%), greater itch reduction, fewer flares, and improved quality of life by three months when treated with a JAK inhibitor compared to a Th2-targeted therapy. 

These data validate the clinical importance of AdvanceAD-Tx as a first-in-class molecular tool for informing systemic therapy decisions in atopic dermatitis, supporting a precision-based approach to patient management.